Overview

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Status:
Recruiting

Trial end date:
2027-02-23

Target enrollment:

Participant gender:

Summary

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy. The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow-up phase.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen
Celgene

Treatments:

Apremilast
Thalidomide